Prostate cancer screening will save lives and money
Today we report that new research has shown that the benefits of targeted screening for the disease outweigh the potential risks by seven to one. Offering PSA blood tests to men aged 45 to 70 with a family history of prostate cancer gave these patients seven 'healthy years' for every one lost. Black men, at higher risk of developing this cancer, benefited from being offered the tests every five years.
According to Prostate Cancer Research, separate modelling shows that a targeted screening programme of all men at higher risk, together with better diagnostics, would save 40 per cent of the annual toll of 12,000 deaths. So the Telegraph campaign could save 4,800 lives every year.
What about the cost? In the 45-70 age range, some 650,000 men have a close relative who has suffered from prostate cancer, while 370,000 are black. Hence a programme aimed at these groups would offer tests to more than a million men. This is a much smaller number than the 6.5 million women who are currently eligible for breast cancer screening. While women require mammograms every three years, men would be tested only every five years.
So a targeted prostate cancer screening programme should be much cheaper than the current NHS Breast Cancer Screening Programme, which costs just under £100 million annually. Indeed, such programmes save money by reducing the need for hospital care. For the 55,000 men who are diagnosed with prostate cancer every year, screening cannot come soon enough.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
7 hours ago
- Telegraph
World first as life-saving cancer drugs to be mixed at patients' bedsides
Cancer patients will get personalised drugs made at their bedside under new laws, The Telegraph can reveal. The UK is the first country in the world to relax the strict manufacturing rules that cause delays to time-sensitive treatments. An increasing number of new medicines, including for cancer and rare genetic disorders, involve creating a bespoke drug for each patient by collecting their cells and modifying them in a laboratory, before they are injected back into the patient. But because the samples have to be taken and edited in specialist facilities – often hundreds of miles away – patients are too often facing delays. They may become too unwell to receive the drug, or the medicine itself may not survive the journey because of its short shelf-life. From now, the last of these steps can be completed closer to the patient, reducing the time it takes to produce a life-saving treatment from months to just days, the medical regulator said. 'Flexible, responsive system' The new laws, introduced by the Medicines and Healthcare products Regulatory Agency (MHRA), will mean the drugs can be manufactured where the patient is – and given to them in hospital or their own homes. Writing in The Telegraph, Lawrence Tallon, the new chief executive of the MHRA, said it was about creating 'a more flexible, responsive system that meets the needs of modern medicine' rather than forcing 'the medicine to fit an outdated system'. 'Some of these advanced therapies are made using a person's own cells. Others are built around their genetic code. A few are so sensitive they can't be frozen or stored – they have to be given to the patient within mere minutes of being made. That's a world away from how medicines are typically mass-made and distributed today,' he said. 'In these cases, delays can be critical. Some patients have become too unwell to receive their treatment in time. In others, the medicine simply didn't survive the journey.' He added: 'Hospitals can now carry out the final steps of manufacturing on-site – under the same strict standards, but far more quickly. 'That means a cancer patient could now have their immune cells collected, modified, and returned at the same hospital. A child with a rare genetic disorder can receive a therapy made at their bedside.' 'Personalised therapies' Mobile units will also be deployed to finish the manufacturing of the drugs for patients who are too sick to leave their homes or need to limit hospital visits because of weakened immune systems. The MHRA said the move mirrored how chemotherapy and antibiotics are prepared locally, but stressed that there would still be strict safeguards and regulatory protocols. There will also be a 'central control site' that will oversee the personalised therapies being completed in hospitals. Wes Streeting, the Health Secretary, said it was a 'game-changer'. 'Cancer treatments tailored in days, not months. Life-saving therapies made at your bedside, not hundreds of miles away,' he said. 'Our Plan for Change promised to build an NHS fit for the future. Today we're delivering on that pledge by bringing cutting-edge care directly to patients when they need it most. 'This type of therapy means patients can be treated and return home more quickly.' One example of a personalised treatment that is set to become more accessible for patients is CAR-T cancer therapy. It involves genetically modifying a blood cancer patients' immune cells so that the immune system recognises and kills the cancer cells that would otherwise go undetected by the body and continue to spread. Previously, hospitals were only able to offer these treatments through complicated, one-off arrangements. The changes have already come into effect after the legislation, known as The Human Medicines (Amendment) (Modular Manufacture and Point of Care) Regulations 2025, was passed last month. It covers a range of innovations, including cell and gene therapies, tissue-engineered treatments, 3D printed products, blood products, and medicinal gases. Lord Vallance, the science minister and Government's former chief scientific officer, said the 'world-first framework gives the NHS and innovators a clear, safe way to bring advanced treatments from the lab to the patient's bedside'. 'It's a powerful example of how smart regulation can help more patients benefit from the best of British science.' 'Modern medicine needs a modern delivery system' By Lawrence Tallon For most medicines, the system works well enough. Medicines are made in bulk, boxed up, and shipped off to where they're needed in the world. It's how care has been delivered for decades. But a new generation of personalised therapies is beginning to challenge that model – and unless we adapt, patients could miss out. Some of these advanced therapies are made using a person's own cells. Others are built around their genetic code. A few are so sensitive they can't be frozen or stored – they have to be given to the patient within mere minutes of being made. That's a world away from how medicines are typically mass-made and distributed today. In these cases, delays can be critical. Some patients have become too unwell to receive their treatment in time. In others, the medicine simply didn't survive the journey. We need a more flexible, responsive system that meets the needs of modern medicine, not force the medicine to fit an outdated system. That's why this week, the UK became the first country in the world to introduce a new legal framework that allows these advanced medicines to be made at the point of care. Under new regulations introduced by the Medicines and Healthcare products Regulatory Agency (MHRA), hospitals can now carry out the final steps of manufacturing on-site – under the same strict standards, but far more quickly. That means a cancer patient could now have their immune cells collected, modified and returned at the same hospital. A child with a rare genetic disorder can receive a therapy made at their bedside. No more shipping cells hundreds of miles away and hoping they survive the journey back. It also offers a safer alternative for people too unwell to travel, or whose immune systems make hospital visits risky. 'Supporting early access to promising treatments' This is part of a wider effort to modernise the way we support innovation in the UK. We've shortened the time it takes to approve clinical trials to 40 days. We've introduced new routes for authorising medicines already approved by trusted international regulators. And where the evidence is strong and the need is urgent, we support early access to promising treatments. We're paying particular attention to rare diseases, where patients often face the longest waits for new treatments. While each condition may affect only a few people, the overall impact is large: around 3.5 million people in the UK, and an estimated 300 million globally, live with a rare condition. Yet developing treatments is often more difficult, with fewer clinical trial participants and less commercial return. That's why we're offering targeted support. For companies working on rare disease therapies, we've reduced or waived fees and increased access to expert scientific advice. The aim is to make it simpler and more affordable to bring forward safe treatments where there is high need and few other options. We're also supporting smarter ways to generate evidence. For very rare conditions, large-scale trials aren't always possible. We're working with researchers to use high-quality real-world data, like NHS records and patient registries, so that safe and effective treatments aren't held back for lack of traditional trial data. Medical innovation doesn't end with discovery or what's in the vial. It's also about tackling the barriers that stop new treatments reaching patients. That means creating a safe system built for tomorrow's medicines – especially for people with the fewest options – whether by changing how they're approved, how trials are run, or how evidence is gathered. After all, a life-changing treatment only matters because we can deliver it when and where the person needs it.
Telegraph
2 days ago
- Telegraph
Why men don't talk to the GP about prostate cancer
Men are often more familiar with Formula 1 world champions than they are with signs of prostate cancer, research has found. A new survey has exposed widespread confusion among men about prostate cancer and prostate health more widely. The poll found that 27 per cent of men could name more leading racing drivers than signs of prostate problems. Meanwhile, a third were too shy to speak to their GP about their problems, while almost half were unaware of how screening worked. A quarter believed they did not need to be checked unless they had symptoms. Why we're campaigning for change The Telegraph is campaigning for the introduction of targeted screening so those most at risk, such as black men and those with a family history of disease, are offered PSA tests. Experts are also calling for current NHS guidance to be rewritten so that GPs are told to discuss prostate cancer risks with men, rather than waiting to see if they bring it up. Prostate cancer often has no symptoms in its early stages. When symptoms do appear, they can include changes in urination, such as needing to urinate more frequently, especially at night, difficulty starting or stopping urination, a weak urine stream, and a feeling that the bladder has not emptied completely. However, urination problems are also common in old age, as well as being linked to other less serious problems. Persistent back pain, fatigue and weight loss can be symptoms of advanced disease. Early diagnosis is critical Late diagnosis is linked to far worse survival. Men diagnosed with prostate cancer at an early stage have five-year survival rates of almost 100 per cent. This compares to rates of around 50 per cent once it has spread beyond the prostate. Every year, around 55,000 men are diagnosed with prostate cancer, making it the most common cancer in men, with 12,000 deaths. However, prostate cancer is the only major cancer with no screening programme. The poll of 2,000 men by Vista Health found 35 per cent have delayed or avoided speaking to a healthcare professional about potential prostate issues. Embarrassment was the most common reason, cited by 16 per cent. Widespread ignorance Twenty-six per cent of respondents did not know where the prostate is located and 65 per cent could not confidently explain its function (it makes semen and controls the flow of urine). A fifth of men wrongly believed the prostate was located in the bladder, when the small gland is actually below. More than a quarter of men said they had sought tests after public figures spoke out. It comes after The Telegraph revealed that almost 5,000 extra men have been referred by the NHS for urological cancer in the six months after Sir Chris Hoy, 49, the six-time Olympic cycling gold medallist, spoke about his diagnosis. The polling found that a quarter of men said they were also more likely to undergo checks if encouraged by their partners, while four in ten said the y would do so for peace of mind. The polling was commissioned by Vista Health, which offers a prostate screening service, including PSA blood testing and MRI where needed. Dr Reem Hasan, the chief medical officer at Vista Health, said: 'These findings are a real wake-up call. Many men are understandably worried about prostate cancer, but too often they don't fully understand what the prostate is, what it does, or whether they may be at increased risk. That confusion can quickly become fear and sadly, fear can delay action. Empowerment over embarrassment 'We urgently need to replace myths with facts, and embarrassment with empowerment. Prostate health should not be a taboo topic. Getting checked does not have to be invasiv e or uncomfortable. A simple PSA blood test, followed by an MRI if needed, can offer clarity and real peace of mind.' The UK National Screening Committee (UK NSC) is currently considering whether to recommend the rollout of testing. In the past, it has rejected the idea because of concern that PSA tests are too unreliable, and would result in too many men undergoing needless procedures. However, in recent years the back-up technology used to confirm a diagnosis has significantly improved, with hopes that further advances being tested in Prostate Cancer UK's Transform trial could mean that, in future, screening could cut deaths by 40 per cent.
Daily Record
3 days ago
- Daily Record
Princess Margaret 'had foetal alcohol syndrome from Queen Mother's drinking' claims new book
Queen Elizabeth's sister, Princess Margaret, showed some symptoms of foetal alcohol syndrome, according to Pulitzer Prize-nominated biographer Meryle Secrest in her new book. Princess Margaret had foetal alcohol syndrome because the Queen Mother drank while she was pregnant with her - claims a new book. Foetal alcohol syndrome develops when alcohol is exposed to a baby in the womb, which can damage their brain and body and stop them from developing normally. It can result in a loss of pregnancy, and babies who survive may be left with lifelong problems - including with movement, learning communication and hyperactivity. Pulitzer Prize-nominated biographer Meryle Secrest made the claims in a new book in which she analysed Margaret's personality and personal struggles in light of greater knowledge about the condition, reports the Mirror. It comes after Joanna Lumley said King Charles 'really is ill' as she shares rare health battle insight. In her book, it's speculated that Queen Elizabeth's younger sister, who died aged 71 in 2002, suffered from an "invisible disability" due to the condition, The Telegraph reports. The biographer's claims about the princess have not been proven and there is no firm evidence that Margaret suffered from an alcohol-related neurodevelopmental disorder. The book claims that while Margaret lacked the tell-tale symptoms of smooth lip philtrum and small eyes, she displayed characteristic mood swings, stunted growth, difficulties learning how to write, and painful migraines. It also cites accounts of the Queen Mother's drinking in later life - with claims from a former equerry that during the day she would enjoy gin and Dubonnet. Foetal alcohol syndrome wasn't well understood until the 1970s, the book states, and it is likely that the young Queen Mother would not have been advised to avoid alcohol during her pregnancy with Margaret. But it claims that in the Queen Mother's letters from when she was pregnant with Elizabeth II, she wrote she could not bear the thought of wine, suggesting she may have drunk less when expecting the future queen. She wrote in a 1925 letter to the future King George VI: "The sight of wine simply turns me up! Isn't it extraordinary! It will be a tragedy if I never recover my drinking powers." Fetal alcohol syndrome (FAS) is a condition that develops in a foetus when a pregnant woman drinks alcohol during pregnancy, explains the Cleveland Clinic. A syndrome is a group of symptoms that happen together as the result of a particular disease or abnormal condition. When someone has foetal alcohol syndrome, they're at the most severe end of what are known as foetal alcohol spectrum disorders (FASDs). The condition is life-long and can't be cured. It can be prevented if you don't drink any alcohol during pregnancy, as even small amounts can damage your developing foetus. The new biography, named Princess Margaret and the Curse: An Inquiry into a Royal Life, has been written by comparing Margaret's life with those who have suffered from the condition. It will be released by the US house Skyhorse Publishing.
